Feasibility of short imaging protocols for [

Alzheimer Disease Feasibility Studies Humans Positron-Emission Tomography Supranuclear Palsy, Progressive / diagnostic imaging tau Proteins

Progressive supranuclear palsy Tau-PET Time window [18F]PI-2620

Journal

European journal of nuclear medicine and molecular imaging

ISSN: 1619-7089

Titre abrégé: Eur J Nucl Med Mol Imaging

Pays: Germany

ID NLM: 101140988

Informations de publication

Date de publication:
11 2021

Historique:

received: 24 01 2021

accepted: 26 04 2021

pubmed: 23 5 2021

medline: 21 10 2021

entrez: 22 5 2021

Statut: ppublish

Résumé

Dynamic 60-min positron emission tomography (PET) imaging with the novel tau radiotracer [ Thirty-seven patients with PSP Richardson syndrome (PSP-RS) were evaluated together with ten HCs. [ 0-50 and 0-40 DVR showed equivalent effect sizes as 0-60 DVR (averaged Cohen's d: 1.22 and 1.16 vs. 1.26), whereas the performance dropped for 0-30 or 0-20 DVR. The 20-40 SUVr indicated the best performance of all static acquisition windows (averaged Cohen's d: 0.99). The globus pallidus internus discriminated patients with PSP-RS and HCs at a similarly high level for 0-60 DVR (AUC: 0.96), 0-40 DVR (AUC: 0.96), and 20-40 SUVr (AUC: 0.94). The multi-region classifier sensitivity of these time windows was consistently 86%. Truncated and static imaging windows can be used for [

Identifiants

DOI: 10.1007/s00259-021-05391-3 PMID: 34021393 PMC: PMC8484138

pubmed: 34021393

doi: 10.1007/s00259-021-05391-3

pii: 10.1007/s00259-021-05391-3

pmc: PMC8484138

doi:

Substances chimiques

tau Proteins 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

Pagination

3872-3885

Informations de copyright

Références

Steele JC, Richardson JC, Olszewski J. Progressive Supranuclear Palsy. A heterogeneous degeneration involving the brain stem, basal ganglia and cerebellum with vertical gaze and pseudobulbar palsy, Nuchal Dystonia and Dementia. Arch Neurol. 1964;10:333–59.

doi: 10.1001/archneur.1964.00460160003001 pubmed: 14107684

Respondek G, Grimm MJ, Piot I, Arzberger T, Compta Y, Englund E, et al. Validation of the movement disorder society criteria for the diagnosis of 4-repeat tauopathies. Mov Disord. 2020;35:171–6. https://doi.org/10.1002/mds.27872 .

doi: 10.1002/mds.27872 pubmed: 31571273

Boxer AL, Yu JT, Golbe LI, Litvan I, Lang AE, Hoglinger GU. Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches. Lancet Neurol. 2017;16:552–63. https://doi.org/10.1016/S1474-4422(17)30157-6 .

doi: 10.1016/S1474-4422(17)30157-6 pubmed: 28653647 pmcid: 5802400

Kroth H, Oden F, Molette J, Schieferstein H, Capotosti F, Mueller A, et al. Discovery and preclinical characterization of [(18) F]PI-2620, a next-generation tau PET tracer for the assessment of tau pathology in Alzheimer's disease and other tauopathies. Eur J Nucl Med Mol Imaging. 2019;46:2178–89. https://doi.org/10.1007/s00259-019-04397-2 .

doi: 10.1007/s00259-019-04397-2 pubmed: 31264169 pmcid: 6667408

Beyer L, Brendel M. Imaging of tau pathology in neurodegenerative diseases: an update. Semin Nucl Med. 2021;51:253–63. https://doi.org/10.1053/j.semnuclmed.2020.12.004 .

doi: 10.1053/j.semnuclmed.2020.12.004 pubmed: 33353724

Brendel M, Barthel H, van Eimeren T, Marek K, Beyer L, Song M, et al. Assessment of 18F-PI-2620 as a biomarker in progressive supranuclear palsy. JAMA Neurol. 2020;77:1408–19. https://doi.org/10.1001/jamaneurol.2020.2526 .

doi: 10.1001/jamaneurol.2020.2526 pubmed: 33165511

Brendel M, Deussing M, Blume T, Kaiser L, Probst F, Overhoff F, et al. Late-stage Anle138b treatment ameliorates tau pathology and metabolic decline in a mouse model of human Alzheimer’s disease tau. Alzheimers Res Ther. 2019;11:67. https://doi.org/10.1186/s13195-019-0522-z .

doi: 10.1186/s13195-019-0522-z pubmed: 31370885 pmcid: 6670231

Wagner J, Krauss S, Shi S, Ryazanov S, Steffen J, Miklitz C, et al. Reducing tau aggregates with anle138b delays disease progression in a mouse model of tauopathies. Acta Neuropathol. 2015;130:619–31. https://doi.org/10.1007/s00401-015-1483-3 .

doi: 10.1007/s00401-015-1483-3 pubmed: 26439832 pmcid: 4612332

Levin J, Schmidt F, Boehm C, Prix C, Botzel K, Ryazanov S, et al. The oligomer modulator anle138b inhibits disease progression in a Parkinson mouse model even with treatment started after disease onset. Acta Neuropathol. 2014;127:779–80. https://doi.org/10.1007/s00401-014-1265-3 .

doi: 10.1007/s00401-014-1265-3 pubmed: 24615514 pmcid: 3984662

Michelson D, Grundman M, Magnuson K, Fisher R, Levenson JM, Aisen P, et al. Randomized, placebo controlled trial of npt088, a phage-derived, amyloid-targeted treatment for Alzheimer’s disease. J Prev Alzheimers Dis. 2019;6:228–31. https://doi.org/10.14283/jpad.2019.37 .

doi: 10.14283/jpad.2019.37 pubmed: 31686093

Levenson JM, Schroeter S, Carroll JC, Cullen V, Asp E, Proschitsky M, et al. NPT088 reduces both amyloid-beta and tau pathologies in transgenic mice. Alzheimers Dement (N Y). 2016;2:141–55. https://doi.org/10.1016/j.trci.2016.06.004 .

doi: 10.1016/j.trci.2016.06.004

Sopko R, Golonzhka O, Arndt J, Quan C, Czerkowicz J, Cameron A, et al. Characterization of tau binding by gosuranemab. Neurobiol Dis. 2020;146:105120. https://doi.org/10.1016/j.nbd.2020.105120 .

doi: 10.1016/j.nbd.2020.105120 pubmed: 32991997

Bright J, Hussain S, Dang V, Wright S, Cooper B, Byun T, et al. Human secreted tau increases amyloid-beta production. Neurobiol Aging. 2015;36:693–709. https://doi.org/10.1016/j.neurobiolaging.2014.09.007 .

doi: 10.1016/j.neurobiolaging.2014.09.007 pubmed: 25442111

Courade JP, Angers R, Mairet-Coello G, Pacico N, Tyson K, Lightwood D, et al. Epitope determines efficacy of therapeutic anti-tau antibodies in a functional assay with human Alzheimer tau. Acta Neuropathol. 2018;136:729–45. https://doi.org/10.1007/s00401-018-1911-2 .

doi: 10.1007/s00401-018-1911-2 pubmed: 30238240 pmcid: 6208734

Albert M, Mairet-Coello G, Danis C, Lieger S, Caillierez R, Carrier S, et al. Prevention of tau seeding and propagation by immunotherapy with a central tau epitope antibody. Brain. 2019;142:1736–50. https://doi.org/10.1093/brain/awz100 .

doi: 10.1093/brain/awz100 pubmed: 31038156 pmcid: 6536853

Hoglinger GU, Respondek G, Stamelou M, Kurz C, Josephs KA, Lang AE, et al. Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria. Mov Disord. 2017;32:853–64. https://doi.org/10.1002/mds.26987 .

doi: 10.1002/mds.26987 pubmed: 28467028 pmcid: 5516529

Mueller A, Bullich S, Barret O, Madonia J, Berndt M, Papin C, et al. Tau PET imaging with (18) F-PI-2620 in patients with Alzheimer’s disease and healthy controls: a first-in-human study. Journal of nuclear medicine: official publication, Society of Nuclear Medicine. 2019. https://doi.org/10.2967/jnumed.119.236224 .

Jagust WJ, Landau SM, Koeppe RA, Reiman EM, Chen K, Mathis CA, et al. The Alzheimer’s disease neuroimaging initiative 2 PET Core: 2015. Alzheimers Dement. 2015;11:757–71. https://doi.org/10.1016/j.jalz.2015.05.001 .

doi: 10.1016/j.jalz.2015.05.001 pubmed: 26194311 pmcid: 4510459

Hammers A, Allom R, Koepp MJ, Free SL, Myers R, Lemieux L, et al. Three-dimensional maximum probability atlas of the human brain, with particular reference to the temporal lobe. Hum Brain Mapp. 2003;19:224–47. https://doi.org/10.1002/hbm.10123 .

doi: 10.1002/hbm.10123 pubmed: 12874777 pmcid: 6871794

Keuken MC, Bazin PL, Backhouse K, Beekhuizen S, Himmer L, Kandola A, et al. Effects of aging on T (1), T (2)*, and QSM MRI values in the subcortex. Brain Struct Funct. 2017;222:2487–505. https://doi.org/10.1007/s00429-016-1352-4 .

doi: 10.1007/s00429-016-1352-4 pubmed: 28168364 pmcid: 5541117

Schwarz AJ, Shcherbinin S, Slieker LJ, Risacher SL, Charil A, Irizarry MC, et al. Topographic staging of tau positron emission tomography images. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring. 2018;10:221–31. https://doi.org/10.1016/j.dadm.2018.01.006 .

doi: 10.1016/j.dadm.2018.01.006

Ichise M, Liow JS, Lu JQ, Takano A, Model K, Toyama H, et al. Linearized reference tissue parametric imaging methods: application to [11C] DASB positron emission tomography studies of the serotonin transporter in human brain. Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism. 2003;23:1096–112. https://doi.org/10.1097/01.WCB.0000085441.37552.CA .

doi: 10.1097/01.WCB.0000085441.37552.CA

van Eimeren T, Antonini A, Berg D, Bohnen N, Ceravolo R, Drzezga A, et al. Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: proposal for a neuroimaging biomarker utility system. Alzheimers Dement (Amst). 2019;11:301–9. https://doi.org/10.1016/j.dadm.2019.01.011 .

doi: 10.1016/j.dadm.2019.01.011

van Berckel BN, Ossenkoppele R, Tolboom N, Yaqub M, Foster-Dingley JC, Windhorst AD, et al. Longitudinal amyloid imaging using 11C-PiB: methodologic considerations. J Nucl Med. 2013;54:1570–6. https://doi.org/10.2967/jnumed.112.113654 .

doi: 10.2967/jnumed.112.113654 pubmed: 23940304

Beyer L, Nitschmann A, Barthel H, van Eimeren T, Unterrainer M, Sauerbeck J, et al. Early-phase [(18) F]PI-2620 tau-PET imaging as a surrogate marker of neuronal injury. Eur J Nucl Med Mol Imaging. 2020. https://doi.org/10.1007/s00259-020-04788-w .

Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer’s disease. N Engl J Med. 2014;370:322–33. https://doi.org/10.1056/NEJMoa1304839 .

doi: 10.1056/NEJMoa1304839 pubmed: 24450891 pmcid: 4159618

Sevigny J, Chiao P, Bussière T, Weinreb PH, Williams L, Maier M, et al. The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease. Nature. 2016;537:50–6.

doi: 10.1038/nature19323 pubmed: 27582220

Wessels AM, Lines C, Stern RA, Kost J, Voss T, Mozley LH, et al. Cognitive outcomes in trials of two BACE inhibitors in Alzheimer’s disease. Alzheimers Dement. 2020;16:1483–92. https://doi.org/10.1002/alz.12164 .

doi: 10.1002/alz.12164 pubmed: 33049114

Bullich S, Barret O, Constantinescu C, Sandiego C, Mueller A, Berndt M, et al. Evaluation of dosimetry, quantitative methods, and test-retest variability of (18) F-PI-2620 PET for the assessment of tau deposits in the human brain. J Nucl Med. 2020;61:920–7. https://doi.org/10.2967/jnumed.119.236240 .

doi: 10.2967/jnumed.119.236240 pubmed: 31712324 pmcid: 7262221

Mormino EC, Toueg TN, Azevedo C, Castillo JB, Guo W, Nadiadwala A, et al. Tau PET imaging with (18) F-PI-2620 in aging and neurodegenerative diseases. Eur J Nucl Med Mol Imaging. 2020. https://doi.org/10.1007/s00259-020-04923-7 .

Betthauser TJ, Cody KA, Zammit MD, Murali D, Converse AK, Barnhart TE, et al. In vivo characterization and quantification of neurofibrillary tau PET Radioligand (18) F-MK-6240 in humans from Alzheimer disease dementia to young controls. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2019;60:93–9. https://doi.org/10.2967/jnumed.118.209650 .

doi: 10.2967/jnumed.118.209650

Pontecorvo MJ, Keene CD, Beach TG, Montine TJ, Arora AK, Devous MD Sr, et al. Comparison of regional flortaucipir PET with quantitative tau immunohistochemistry in three subjects with Alzheimer’s disease pathology: a clinicopathological study. EJNMMI Res. 2020;10:65. https://doi.org/10.1186/s13550-020-00653-x .

doi: 10.1186/s13550-020-00653-x pubmed: 32542468 pmcid: 7295920

Leuzy A, Smith R, Ossenkoppele R, Santillo A, Borroni E, Klein G, et al. Diagnostic performance of RO948 F 18 tau positron emission tomography in the differentiation of Alzheimer disease from other neurodegenerative disorders. JAMA Neurol. 2020;77:955–65. https://doi.org/10.1001/jamaneurol.2020.0989 .

doi: 10.1001/jamaneurol.2020.0989 pubmed: 32391858

Tagai K, Ono M, Kubota M, Kitamura S, Takahata K, Seki C, et al. High-contrast in-vivo imaging of tau pathologies in Alzheimer’s and non-Alzheimer’s disease tauopathies. medRxiv. 2020:2020.03.05.20028407. https://doi.org/10.1101/2020.03.05.20028407 .

Aguero C, Dhaynaut M, Normandin MD, Amaral AC, Guehl NJ, Neelamegam R, et al. Autoradiography validation of novel tau PET tracer [F-18]-MK-6240 on human postmortem brain tissue. Acta neuropathologica communications. 2019;7:37. https://doi.org/10.1186/s40478-019-0686-6 .

doi: 10.1186/s40478-019-0686-6 pubmed: 30857558 pmcid: 6410510

Song M, Beyer L, Kaiser L, Barthel H, van Eimeren T, Marek K, et al. Binding characteristics of [18F]PI-2620 distinguish the clinically predicted tau isoform in different tauopathies by PET. Journal of Cerebral Blood Flow Metabolism. 2021; in press. https://doi.org/10.1177/0271678X211018904 .